Interpretation of
what the WHO is saying about this does seem to involve a certain amount of reading between the lines (as well as compensating for language munged in transcription). When I encounter, say, this passage:
"
As to stop potentially seasonal vaccine production, again there is still evidence lacking to make such a big move into saying if we need or we don't need much less seasonal vaccine for the next epidemic season. We are currently collecting with the manufacturers all data and all evidence on availability of enough material to make seasonal vaccine now. Potentially a recommendation towards stopping production of seasonal vaccine may come in a few weeks, if it does."
...I infer that the decision
does potentially involve choosing one vaccine over another.
Not that I expect you to recall everything I've posted, especially something not perceived to be relevant at the time, but I said only the US had the luxury of current flu vaccine manufacturers that were almost finished with this year's vaccine. I said I was not sure about Europe's or Canada's production status, and that the southern hemisphere was faced with the dilemma of perhaps having to choose one over the other.
Asked explicitly whether there is the capacity to do both at the same time, Dr. Kieny pointed to the unknown variables which could impact that. If it turns out that the yield is poor, or the effective dosage is high (or, worse, both), then the answer would appear to be no. She also clearly expressed uncertainty regarding how much vaccine has already been produced, saying "We hope to be able to have that by next week." (That is, this week). I understand that because WHO officials have to be cautious about public statements they make, Dr. Kieny may actually know more about where the U.S. production is than she is saying. Can you provide links to other sources which have been more forthcoming about this?
Sure, she said something to the effect there was uncertainty regarding capacity for 700 million doses or 900 million.
Perhaps you missed this from your link:
We would not want to have no seasonal influenza vaccine and we think we already have quite a lot of it produced.
and
And we know that they have produced for sure around 500 million doses of seasonal vaccine in 2009. So this we know for sure.
That tells me Canada and Europe might also have a fair amount of their vaccine ready since the US only made ~100 million doses last year. I doubt we would have 5 times that amount this year.
Not simultaneously at the same facility, if the Director of the Initiative for Vaccine Research at the World Health Organization knows anything about it:
"In terms of knowing if it possible to continue to make seasonal wild seed while already producing H1, it depends because you can't produce in the same manufacturing plant two influenza vaccines at the same time."
From your link:
This is why manufacturers for seasonal, for example, do the three strains one after the other. Some of the manufacturers have more than one production plant...
Those production plants can be in the same geographical location, including in the same building. Obviously each seed strain has to be isolated from each different seed strain. I certainly never suggested you would just mix the bunch up in the same room.
And yet, here we are, four decades since the last notable flu pandemic, following discussions on whether a pandemic vaccine would be added to the trivalent vaccine or distributed separately as a univalent vaccine, and whether it deserves enough priority to justify curtailing production of at least some components of the trivalent seasonal vaccine. It underscores my point: twenty years of experience in dealing with influenza is twenty years of no experience in dealing with pandemic influenza. This is not business as usual.
Once again, you are confusing news reports and official WHO and CDC statements with what is actually being discussed about the vaccine. For example, in your link Dr Kieny made the following comments:
We have been setting up an Advisory Committee that will provide policy recommendation to WHO on the use of this vaccine....
We are organizing, as I speak, a meeting that has been called by the Director-General in Geneva on 19 May with the heads of all the companies making influenza vaccines....
These are some of the factors that will be taken into consideration by this policy advisory group when it will work towards making potentially a recommendation to the Director-General that at one point it might be the time to "switch", if you mean "switch" is "stop seasonal”. But in the mean time, there may be recommendation coming much before that, could be next week, could be later also, it depends on the opinion of these experts and not on what I would think for example, or what the WHO Secretariat thinks, about starting large scale manufacturing.
That's political speak for, "I can't make an announcement yet," and "no one person makes the WHO decisions." It's also pretty strong language for "the answer is a go for a new vaccine."
This is also pretty strong language for "the answer is a go for a new vaccine."
Efforts are still going on in the WHO Collaborating Centres, at the CDC and elsewhere, to generate these strains for the manufacturers and we still expect that these would be available to the manufacturers most likely during the second half of May. We will post on our web site, as soon as the date is for sure, as well as a list of laboratories from which these seed strains will be available and the date, and this as soon as possible.
We have communicated with all manufacturers already, and have assured them and taken all steps to ensure that these seed strains will be available to all of them who so request to the WHO Collaborating Centres.
I must say that the manufacturers that we have had discussions with, have been very forthcoming and we hope that we will be able in a few days – maximum weeks – to announce that some agreement has been signed.
The public has most of the same information or at least a good idea about that information that this advisory group will base their decisions on. You seem to think the committee has some secret information not available to the rest of us, or perhaps you think their decision is unpredictable. Anyone who works in this field knows what the committee is going to recommend because we have most of the same information they have.
Idle manufacturing capacity does not appear to be much of an issue.
From your link:
There are also manufacturers who either have such a large capacity that even with these orders they have a lot of capacity to offer, some others have no pre-purchased doses. It is really a mixed picture. Before jumping ahead and saying how many doses are being locked in contracts, we really need to have more data. There has been one manufacturer who has said publicly, in a teleconference with the other manufacturers, that their company had currently locked into contract enough vaccine to vaccinate a little bit over 200 million people, but this particular manufacturer has a much larger production capacity. Even though we may seem large, this manufacturer still has a lot to offer for other countries.
And as I said, Sanofi just had a new facility approved for flu vaccine production announced on May 4th. After several years with a serious flu vaccine shortage, the US government has been taking action to increase production capacity. They have guaranteed purchases, but also in your link I noticed Dr K mentioned the US actually paid for some of the new plants.
The same could be said for the Maginot Line.
I'm sorry but I totally don't see the relevance. Could you possibly have a perfect plan in place before you ever had an actual event to test it in? Of course not. Even after testing and working the bugs out, the next pandemic would create new challenges.
I've seen a pretty good response in my state. I can't say about other areas of the country just yet.
Without exploring all of the possible avenues of a response to that: When it comes to the ability of this health care system to respond to a major pandemic event, I find it hard to muster even cautious optimism.
And I am far from being alone in this:
"
My hospital has almost no surge capacity; it is running full all the time," Panacek said. "If we had a 10% increase in the need for admissions because of flu, we would have nowhere in the hospital to put those patients. They would back up in the ER, and they would lie on gurneys for days."
Surge capacity in hospitals hasn't really been needed yet. The initial crowds at the EDs were mostly not that sick and the issue was short lived. Sometime in the future, however, we'll be seeing the real surge with the really ill people. But I'm talking about realistic pandemic flu planning, not idealistic when I say the planned response has been excellent.
You're never going to get the public to tolerate the economic expenditure to have idle surge capacity available for pandemics. Just as we know what we should be doing to retrofit buildings and bridges for big earthquakes. People are unwilling to spend much money on future risks. Heck, most of them aren't willing to spend money on current risks like buying the very safest vehicles.
The one big problem I see that hasn't been addressed in our planning is sick people aren't willing to stay home for various reasons. I think we need to plan for that rather than plan unrealistically for sick people to stay home.
We have to be realistic and plan for overfilled medical facilities, just like we need to have in our pandemic plans a realistic approach to the fact sick people will not stay home. There's no point in planning a solution you know will not be carried out. So I don't see 'no surge capacity' as a problem of planning, that is a problem of public will.